Eli Lilly to Pay up to $3. 8B for AtaiBeckley in Big Pharma’s Latest Psychedelic Foray The pharmaceutical industry has long been criticized for its sluggish response to emerging research in mental health treatment.
However, recent developments suggest that a seismic shift is underway, driven by an unlikely catalyst: psychedelics. Eli Lilly's $3.
8 billion acquisition of AtaiBeckley marks a significant turning point for Big Pharma's foray into psychedelics.